Navigation Links
Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
Date:6/15/2009

s for the three and nine month periods ended April 30, 2009, L-DOS47 represents approximately 63% and 46%, respectively while Topical Interferon Alpha-2b represents approximately 24% and 43%, respectively.

The majority of the L-DOS47 expenditures through the quarter were associated with the scale-up manufacturing of GMP engineering batches in preparation for clinical trial batch manufacturing.

The majority of the Topical Interferon Alpha-2b expenditure increase through the quarter reflects the ongoing costs of the AGW Phase II clinical trial in Sweden and Germany in addition to the costs of the ongoing Phase II pharmacokinetic study and the scale-up manufacturing efforts associated with the LSIL therapeutic indication program.

Operating, general & administration

Operating, general & administration expenses totaled $1,231,000 and $3,854,000 respectively for the three and nine month periods ended April 30, 2009 (three and nine month periods ended April 30, 2008: $1,060,000 and $3,618,000 respectively).

Operating, general and administration expenses were higher for both the three and nine month periods ended April 30, 2009 and mainly reflect the higher one time costs associated with the filing of a Form 20-F registration statement with the U.S. Securities and Exchange Commission, which became effective during the third quarter of fiscal 2009. Also, increased expenditures are associated with the implementation of a new financial reporting system and capital raising initiatives. Offsetting some of the aforementioned increases in expenditures are lower wages and benefits from the foregoing of accrued vacation days by management during the current fiscal year and lower wages and benefits due to a one-time charge relating to the resignation of the Company's Chairman, and management bonuses paid, in the nine month period ended April 30, 2008.

Amortization of c
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. Helix BioPharma reports Q2 2008 highlights, financial results
11. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... WOODBRIDGE, N.J. , Feb. 26, 2015 ... and its affiliated companies, Wilentz, Goldman & ... a trade secrets lawsuit against Genewiz Inc. in excess ... obtained and utilized GenScript,s trade secrets, and that it ... court entered an order denying motions for judgment notwithstanding ...
(Date:2/26/2015)... 2015   Synageva BioPharma Corp. (NASDAQ: ... therapeutic products for rare disorders, today reported 2014 ... other key objectives, and financial guidance.  Synageva,s management ... 4:30 p.m. EST to review the financial results ... in today,s call by telephone, please dial (877) ...
(Date:2/26/2015)... LAUDERDALE, Fla. , Feb. 26, 2015 ... discussed growth priorities driven by key research advancements and ... segments at today,s Bank of America Merrill Lynch 2015 ... met the challenge of building grain supplies the last ... to continue at the pace of the last decade, ...
(Date:2/26/2015)... Calif. , Feb. 26, 2015  NuGene ... age-defying aesthetic products for skin and hair rejuvenation, ... Relations as agency of record for investor relations ... to improve our distribution, sales and diversification strategies ... to current and prospective shareholders," stated Ali Kharazmi ...
Breaking Biology Technology:Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 4DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 5NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3
... BioTrends Research Group, Inc.,released Wave 1 of its ... market research project tracking the launch of,Renvela from ... product,availability. The baseline report was published in December ... month post Renvela launch, and provides,quantitative information from ...
... For the first time, researchers at Delft University of Technology ... in real time. They observed this at the level of ... mechanism is essential as errors in this process can lead ... Institute of Nanoscience Delft are to publish an article on ...
... SAN DIEGO, May 22 Amylin Pharmaceuticals,Inc. (Nasdaq: ... Markets Investor,Conference in New York on Wednesday, May 28, ... M. Kendall, M.D., Executive Director, Medical Affairs of,Amylin Pharmaceuticals, ... presentation and breakout session will be webcast, and a,recording ...
Cached Biology Technology:Awareness of Genzyme's Renvela(R) (Sevelamer Carbonate) is High, Although Uptake of this New Phosphate Binding Agent has Been Slower than Nephrologists and Renal Dietitians Initially Expected 2
(Date:2/24/2015)... YORK , Feb. 24, 2015 This report analyzes ... by the following Segments: Face Biometrics, and Voice Biometrics. The report ... , Japan , Europe , ... & Africa , and Latin America ... 2013 through 2020. Also, a seven-year historic analysis is provided for ...
(Date:2/19/2015)... 2015 Research and Markets ( ... "Military Electro-Optical / Infrared Systems Market by ... - Forecast to 2020" report to their ... market is expected to reach $16.35 billion by ... This report segments the military electro-optical/infrared systems ...
(Date:2/12/2015)... 12, 2015   MedNet Solutions , a ... study management systems, has recently bolstered its ... iMedNet as the eClinical ... and healthcare consultants.  Building on the Program,s existing ... and numerous co-marketing opportunities), MedNet,s new and improved ...
Breaking Biology News(10 mins):World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2
... the largely unexplored question of what characteristics make a ... mimicking nature, a robotic fish can transform into a ... experiments, researchers from Polytechnic Institute of New York University ... including learning how robots might someday steer fish away ...
... people have bad teeth replaced with implants. Often following the ... six months, until the implant has become fixated in the ... has been tested on humans allows titanium screws to adhere ... the method report that the results are good. The ...
... Scientists from Binghamton University and Cardiff University, and ... discovery of the floor of the world,s oldest forest ... of Nature , a leading international journal of ... of dinosaur footprints," said William Stein, associate professor of ...
Cached Biology News:What makes a robot fish attractive? (Hint: It's in the moves) 2New method for stronger dental implants 2Floor of oldest forest discovered in Schoharie County 2Floor of oldest forest discovered in Schoharie County 3Floor of oldest forest discovered in Schoharie County 4
NAK/TBK1 (CT) Affinity Purified Polyclonal Antibody...
... White lyophilized solid. PROTECT FROM LIGHT. PACKAGED ... of γ-secretase. Equipotently inhibits the release of ... 2.6 μM) and Aβ x-42 (ED ... cells stably transfected with the Amyloid Precursor ...
...
Corticoliberin...
Biology Products: